Abdul Shahein
Pediatric Gastroenterology · Columbus, OHNPI 1811236714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $430, more than ten times the $17 reported in 2021.
Across 47 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- QOL Medical, LLC$227
- Sanofi$210
- Ipsen Biopharmaceuticals, Inc$200
- Stryker$141
- Regeneron Healthcare Solutions, Inc.$89
- Johnson & Johnson$72
- plus $358 from 14 others
Across 1 payment — averaging $14,527 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$15K
What the payments were for
- Food & beverage$1,298100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| QOL Medical, LLC | 4 | $227 |
| Sanofi | 12 | $210 |
| Ipsen Biopharmaceuticals, Inc | 4 | $200 |
| Stryker | 1 | $141 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Johnson & Johnson | 3 | $72 |
| Travere Therapeutics, Inc. | 2 | $41 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| AbbVie | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Mauna Kea Technologies, Inc. | 1 | $25 |
| Pharming Healthcare, Inc. | 1 | $24 |
| Alcresta Therapeutics, Inc. | 1 | $22 |
| Coloplast | 1 | $21 |
| Albireo Pharma, Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Biocon Biologics Inc | 1 | $16 |
| Mirum Pharmaceuticals, Inc. | 1 | $15 |
| Applied Medical Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sucraid$150
- AEQUALIS PERFORM$141
- Bylvay$135
How this compares
$1,298 in reported general payments places this provider in the 60th percentile of 114 pediatric gastroenterology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 12 | $170 |
Paid to pharmacies, not to this prescriber.
Other pediatric gastroenterology in Columbus
- Carlo DilorenzoColumbus$14K
- Hilary MichelColumbus$14K
- Muhammad KhanColumbus$12K
- Ethan MezoffColumbus$7K
- Praveen GodayColumbus$7K
- Rajitha VenkateshColumbus$6K
- Kent WilliamsColumbus$5K
- Dieudonne Nonga MakonColumbus$5K
- Alvin FreemanColumbus$3K
- Peter LuColumbus$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.